The "Economic Health" of US Healthcare and Role of Middlemen.
This manuscript goes through the major components of the healthcare return-on-investment ("ROI") equation, from spending to outcomes, and attempts to identify major causes for its under-performance compared to other types of enterprise. It also explores the role of "middlemen" in prescription drug pricing (broadly defined as any market participant other than the drug manufacturer and the provider / patient, including - but not limited to - insurance companies, pharmacy benefit managers ("PBM") and health plans) and teases out the mechanisms by which PBMs in particular contribute to overall healthcare costs and the types of risks and returns they endure. Like any economic system, the healthcare system is a net zero-sum construct, whereby costs and benefits are traded off or exchanged between components of the value chain involuntarily (e.g. by regulatory or legal mandate) or voluntarily (e.g. by economic incentive). Ultimately, the question for policy makers as it relates to healthcare reform is to determine what mix of such exchanges leads to the best overall outcomes. This question of optimization, however, is undoubtedly challenging and complex, and can bring to bear economic, social, political and moral dimensions. In light of these considerations, the article concludes by touching upon some perspectives for the future and ideas for reform, including payer reform, delivery disintermediation by technology and consumer-driven healthcare.